Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta) | Zendy

Jakob Trimpert | Zendy; Julia M. Adler | Zendy; Kathrin Eschke | Zendy; Azza Abdelgawad | Zendy; Theresa C. Firsching | Zendy; Nadine Ebert | Zendy; Tran Thi Nhu Thao | Zendy; Achim D. Gruber | Zendy; Volker Thiel | Zendy; Nikolaus Osterrieder | Zendy; Dušan Kunec | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)

Author(s) -

Jakob Trimpert,

Julia M. Adler,

Kathrin Eschke,

Azza Abdelgawad,

Theresa C. Firsching,

Nadine Ebert,

Tran Thi Nhu Thao,

Achim D. Gruber,

Volker Thiel,

Nikolaus Osterrieder,

Dušan Kunec

Publication year - 2021

Publication title -

science advances

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.928

H-Index - 146

ISSN - 2375-2548

DOI - 10.1126/sciadv.abk0172

Subject(s) - beta (programming language) , alpha (finance) , virology , covid-19 , virus , biology , medicine , outbreak , infectious disease (medical specialty) , computer science , disease , construct validity , nursing , pathology , patient satisfaction , programming language

A single intranasal vaccination with live attenuated virus provides protection against VOC B.1.1.7 (Alpha) and B.1.351 (Beta).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research